1. Pink Sheet
  2. >>Geography

COVID-19: Gilead To Fill Remdesivir Supply Gap In EU

Coronavirus Reignites Compulsory Licensing Debate

 
• By Ian Schofield

As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.

Cell_Covid19_Red
Manufacturing of remdesivir for COVID-19 is being stepped up • Source: Shutterstock

Amid concern over the availability of sufficient quantities of Gilead Sciences, Inc.’s remdesivir for treating coronavirus patients in Europe, the company says it is discussing "multiple options" with the European Commission “with the goal of getting remdesivir to European patients as quickly as possible.” Remdesivir was recently approved in the EU for use in COVID-19.

The EU health commissioner, Stella Kyriakides, met company executives on 6 July to discuss supplies of remdesivir for 16 EU countries, including Austria, Belgium, Denmark, Germany and the Netherlands

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.